Drugs / ABO2203
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06747156 | Dec 2024 → Nov 2027 expected | autoimmune disease | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07072169 | May 2025 → Jun 2026 overdue | B-cell non-Hodgkin lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Abogen Biosciences Co. Ltd. | Results AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL abogenbio.com ↗
Abogen today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Abogen Biosciences Co. Ltd. | AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL abogenbio.com ↗ |
| 2026-03-31 | Abogen Biosciences Co. Ltd. | Abogen Announces AACR 2026 Oral Presentation of First-in-Human Clinical Data for mRNA-Encoded TCE (ABO2203) in NHL abogenbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO2203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07072169 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA encoding CD19/CD3 T cell engager” NCT06747156 ↗ |
| Route | Intravenous | “SC or IV” NCT07072169 ↗ |
| Route | Subcutaneous | “SC or IV” NCT07072169 ↗ |